CYP3A Function in Aging AfricanAmericans
CYP3A Function in Aging AfricanAmericans
批准号:
6896140
负责人:
DAVID J GREENBLATT
金额:
$23.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-01 至 2007-03-31
关键词:
African Americanadult human (21+)age differenceagingbiotransformationblood flow measurementcaucasian Americanclearance rateclinical researchcytochrome P450drug metabolismepidemiologygastrointestinal drug absorptiongender differencegene expressiongenetic polymorphismhuman subjectlidocaineliver metabolismmidazolammolecular geneticspharmacokineticsracial /ethnic differencetestosterone
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Cytochrome P450-3A (CYP3A)
drug-metabolizing enzymes are responsible for the biotransformation and
clearance of a large number of drugs used in contemporary clinical
therapeutics. Individual variation in the expression and activity of CYP3A,
both in the liver and gastrointestinal (GI) tract mucosa, appears to underlie
much of the large individual variability in pharmacokinetics and response to
therapeutically-administered medications that are CYP3A substrates. Many
clinical studies demonstrate that age, gender, and ethnicity (race) may account
for components of this variation in predictable ways. For example, some data
suggest that clearance of certain CYP3A drugs: a Becomes reduced in old age; b
Is higher in women than in men; c Is greater in African-Americans than in
Caucasians. However the available data are not by any means consistent.
Furthermore, variants in the CYP3A4, CYP3A5, and Pregnane-X receptor genes may
modulate age-, gender-, or ethnicity-related variations in CYP3A function in
ways that are not understood. This study will prospectively evaluate cohorts of
young (18-45 years), "young" elderly (60-69 years) and "old" elderly (>70
years) volunteers, consisting of African-American and Caucasian men and women.
The study paradigm will assess: a. Hepatic blood flow (HBF), based on clearance
of low-dose intravenous lidocaine; b Pharmacokinetics and pharrnacodynamics of
intravenous and oral midazolam, a "pure" CYP3A substrate; c The prevalence of
variants in the CYP3A4, CYP3A5, and pregnane-X receptor genes, using molecular
genetic techniques; d. Plasma concentrations of biologically active
testosterone. From a. and b., it is possible to estimate midazolam clearance by
both routes, net oral bioavailability, and bioavailability attributable to
hepatic and gastrointestinal presystemic extraction. With appropriate
statistical techniques, the contributions of age, gender, and ethnicity to
overall variance can be determined, as well as modulation of the relationships
by genetic CYP3A variants and by biologically active testosterone. This study
should provide important mechanistic information on the role of age, gender,
and ethnicity as sources of variability in CYP3A-mediated drug metabolism and
response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COLLABORATORY EXTENSION TO CHIMERA
-
批准号:7180218
-
项目类别:
-
资助金额:$5.64万
-
财政年份:2005
-
负责人:DAVID J GREENBLATT
-
依托单位:
COLLABORATORY EXTENSION TO CHIMERA
-
批准号:6976082
-
项目类别:
-
资助金额:$9.36万
-
财政年份:2004
-
负责人:DAVID J GREENBLATT
-
依托单位:
MDR1 and Related Proteins during HIV PI Exposure
-
批准号:6954257
-
项目类别:
-
资助金额:$24.53万
-
财政年份:2004
-
负责人:DAVID J GREENBLATT
-
依托单位:
CX516 (Ampalex) in Healthy Elderly Males and Females
-
批准号:7040667
-
项目类别:
-
资助金额:$2.18万
-
财政年份:2004
-
负责人:DAVID J GREENBLATT
-
依托单位:
CYP3A Function in Aging AfricanAmericans
-
批准号:6475200
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
CYP3A Function in Aging AfricanAmericans
-
批准号:7047743
-
项目类别:
-
资助金额:$23.22万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS
-
批准号:6658022
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS
-
批准号:6760108
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
CYP3A Function in Aging AfricanAmericans
-
批准号:6730520
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS
-
批准号:6582651
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
CYP3A Function in Aging AfricanAmericans
-
批准号:6624456
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2002
-
负责人:DAVID J GREENBLATT
-
依托单位:
HAART Regimens in Substance Abusers
-
批准号:6450988
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
Metabolic Consequences of HAART: CYP3A and P-gp
-
批准号:6347096
-
项目类别:
-
资助金额:$26.35万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
HAART Regimens in Substance Abusers
-
批准号:6523286
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
Metabolic Consequences of HAART: CYP3A and P-gp
-
批准号:6635316
-
项目类别:
-
资助金额:$26.35万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
HAART Regimens in Substance Abusers
-
批准号:6655137
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
Metabolic Consequences of HAART: CYP3A and P-gp
-
批准号:6517824
-
项目类别:
-
资助金额:$26.35万
-
财政年份:2001
-
负责人:DAVID J GREENBLATT
-
依托单位:
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE
-
批准号:6286930
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2000
-
负责人:DAVID J GREENBLATT
-
依托单位:
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE
-
批准号:6523192
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2000
-
负责人:DAVID J GREENBLATT
-
依托单位:
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE
-
批准号:6379020
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2000
-
负责人:DAVID J GREENBLATT
-
依托单位: